Mads Frost Bertelsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6598334/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell, 2015, 28, 500-514.	7.7	169
2	Bacterial superglue enables easy development of efficient virus-like particle based vaccines. Journal of Nanobiotechnology, 2016, 14, 30.	4.2	161
3	Virus-like particle display of HER2 induces potent anti-cancer responses. Oncolmmunology, 2018, 7, e1408749.	2.1	82
4	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	5.8	79
5	Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Vaccine, 2017, 35, 3726-3732.	1.7	60
6	A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS ONE, 2015, 10, e0143071.	1.1	53
7	Multiple var2csa-Type PfEMP1 Genes Located at Different Chromosomal Loci Occur in Many Plasmodium falciparum Isolates. PLoS ONE, 2009, 4, e6667.	1.1	52
8	Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum. Frontiers in Immunology, 2019, 10, 1256.	2.2	51
9	Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein. Cells, 2019, 8, 998.	1.8	49
10	Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malaria Journal, 2016, 15, 545.	0.8	48
11	A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Scientific Reports, 2019, 9, 5260.	1.6	45
12	DNA secondary structures are associated with recombination in major Plasmodium falciparum variable surface antigen gene families. Nucleic Acids Research, 2014, 42, 2270-2281.	6.5	36
13	The C-terminal tail of α-synuclein protects against aggregate replication but is critical for oligomerization. Communications Biology, 2022, 5, 123.	2.0	30
14	Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. MBio, 2021, 12, e0181321.	1.8	28
15	Positive Selection of Plasmodium falciparum Parasites With Multiple var2csa-Type PfEMP1 Genes During the Course of Infection in Pregnant Women. Journal of Infectious Diseases, 2011, 203, 1679-1685.	1.9	21
16	Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines. Viruses, 2020, 12, 185.	1.5	19
17	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. Frontiers in Immunology, 2022, 13, 857440.	2.2	15
18	Virusâ€like particles displaying major house dust mite allergen Der p 2 for prophylactic allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1232-1236.	2.7	13

MADS FROST BERTELSEN

#	Article	IF	CITATIONS
19	A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice. Vaccines, 2020, 8, 389.	2.1	13
20	Virus-like antigen display for cancer vaccine development, what is the potential?. Expert Review of Vaccines, 2018, 17, 285-288.	2.0	12
21	Leeches as a source of mammalian viral DNA and RNA—a study in medicinal leeches. European Journal of Wildlife Research, 2017, 63, 1.	0.7	9
22	Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems. Vaccines, 2021, 9, 539.	2.1	6
23	An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice. Journal of Virology, 2022, 96, .	1.5	6
24	Immunization with virus-like particles conjugated to $CIDR\hat{i}\pm 1$ domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies. Malaria Journal, 2020, 19, 132.	0.8	5
25	The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration. Vaccines, 2021, 9, 131.	2.1	4
26	Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature. Pharmaceutics, 2022, 14, 1301.	2.0	4
27	Imiquimod Boosts Interferon Response, and Decreases ACE2 and Pro-Inflammatory Response of Human Bronchial Epithelium in Asthma. Frontiers in Immunology, 2021, 12, 743890.	2.2	3
28	Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS ONE, 2021, 16, e0255336.	1.1	2
29	Virusâ€like particles displaying recombinant Der p 1 zymogen to optimize IgG blocking antibody response. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 664-667.	2.7	0
30	Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1Î ² for Treatment of Allergic Contact Dermatitis. Vaccines, 2022, 10, 828.	2.1	0